

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/253833 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/030335

(22) International Filing Date:
21 May 2024 (21.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/506,265 05 June 2023 (05.06.2023) US
63/603,280 28 November 2023 (28.11.2023) US
63/574,382 04 April 2024 (04.04.2024) US

(71) Applicant: **PRIOVANT THERAPEUTICS, INC.**
[US/US]; 1007 Slater Road, Suite 250, Durham, North Carolina 27703 (US).

(72) Inventors: **JOHNSON, Brendan**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **MUDD, Paul N.**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **FRANCO, Matthew Anthony**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **KHETARPAL, Nikhil**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(74) Agent: **MUELLER, Lisa**; Casimir Jones SC, 2275 Deming Way, Suite # 300, Middleton, Wisconsin 53562 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: METHODS FOR TREATING DERMATOMYOSITIS WITH BREPOCITINIB




FIG. 1

(57) Abstract: The present disclosure provides methods related to treatment of a chronic immune-mediated disease of the skin and muscles. In particular, the present disclosure provides methods for the oral administration of a JAK inhibitor, or a pharmaceutically acceptable salt thereof for the treatment of dermatomyositis.



WO 2024/253833 A2